Table 1 Clinical characteristics of patients included in the study.
| Â | Cohort 1 (n = 312) | Cohort 2 (n = 15) | ||
|---|---|---|---|---|
| Â | No. | % | No. | 15 |
Age at diagnosis | Â | Â | Â | Â |
< 50 yr | 197 | 63% | 6 | 40% |
≥ 50 yr | 115 | 37% | 9 | 60% |
Treatment year | Â | Â | Â | Â |
Before 1997 | 125 | 40% | 0 | 0% |
After 1997 | 187 | 60% | 15 | 100% |
TNM Stage | Â | Â | Â | Â |
I | 67 | 21% | 2 | 13% |
II | 139 | 45% | 8 | 53% |
III | 98 | 31% | 5 | 33% |
IV | 8 | 3% | 0 | 0% |
Positive Lymph Nodes | Â | Â | Â | Â |
0 | 132 | 42% | 5 | 33% |
1-3 | 83 | 27% | 5 | 33% |
4-9 | 58 | 19% | 3 | 20% |
≥ 10 | 35 | 11% | 2 | 13% |
Unavailable | 4 | 1% | Â | Â |
Nuclear Grade | Â | Â | Â | Â |
1 | 25 | 8% | 8 | 53% |
2 | 83 | 27% | 7 | 47% |
3 | 202 | 65% | 0 | 0% |
Unavailable | 2 | 1% | Â | Â |
ER * | Â | Â | Â | Â |
ER+ | 190 | 61% | 14 | 93% |
ER- | 122 | 39% | 1 | 7% |
HER2* | Â | Â | Â | Â |
HER2+ | 74 | 24% | 1 | 7% |
HER2- | 238 | 76% | 14 | 93% |
PR* | Â | Â | Â | Â |
PR+ | 244 | 78% | 14 | 93% |
PR- | 68 | 22% | 1 | 7% |
Treatment | Â | Â | Â | Â |
Neoadjuvant Chemotherapy | 31 | 10% | 0 | 0% |
Adjuvant Chemotherapy | 220 | 71% | 12 | 80% |
Radiation Therapy | 133 | 43% | 8 | 53% |
Hormonal Rx | 210 | 67% | 14 | 93% |
No chemotherapy | 50 | 16% | 3 | 20% |